1. Antibody-drug Conjugate/ADC Related Anti-infection
  2. Antibody-Drug Conjugates (ADCs) Bacterial
  3. Indatuximab ravtansine

Indatuximab ravtansine  (Synonyms: BT-062; nBT062-DM4)

Cat. No.: HY-141607

Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities.

For research use only. We do not sell to patients.

Indatuximab ravtansine Chemical Structure

Indatuximab ravtansine Chemical Structure

CAS No. : 1238517-16-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) based on a murine/human chimeric form of B-B4 (specific for CD138), linked to the maytansinoid agent DM4 by disulphide bonds. Indatuximab ravtansine shows anti-tumor activities[1].

In Vitro

Indatuximab ravtansine (1 pM-100 nM; 5 days) shows cytotoxic effects in RPMI 8226, MOLP-8 and U266 cell lines (significant CD138 expression), with IC50 values of 200 pM, 40 pM, and 20 pM for RPMI 8226, MOLP-8, and U266 cells, respectively[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: RPMI 8226, MOLP-8 and U266 cell lines
Concentration: 1 pM-100 nM
Incubation Time: 5 days
Result: Showed cytotoxic effects in RPMI 8226, MOLP-8 and U266 cell lines.
In Vivo

Indatuximab ravtansine (5.3-21.2 mg/kg; i.v.; once) inhibits multiple myeloma tumour growth in vivo and improves host survival[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SCID mice inoculated with MOLP-8 multiple myeloma xenografts[1]
Dosage: 5.3 mg/kg, 10.6 mg/kg or 21.2 mg/kg
Administration: i.v.; once
Result: Inhibited multiple myeloma tumour growth in vivo and improved host survival.
CAS No.
SMILES

[Indatuximab ravtansine]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Indatuximab ravtansine
Cat. No.:
HY-141607
Quantity:
MCE Japan Authorized Agent: